IDH1 Mutation in Gliomas in Mosul City - Iraq

Mohammed Sami Saeed

doi:10.3889/oamjms.2015.041

Authors

Mohammed Sami Saeed Mosul Medical College, University of Mosul, Dept. of Pathology, Mosul Medical College Al-Shifaa Quarter, Mosul, Ninevah 41002

DOI:

https://doi.org/10.3889/oamjms.2015.041

Keywords:

IDH1, gliomas, immunohistochemical, adult, pediatric

Abstract

BACKGROUND: IDH1 (isocitrate dehydrogenase 1) mutation might be encounter in the low grade glioma and directs the progression of the tumor to a higher grade.

OBJECTIVE: To assess the frequency of IDH1 mutations in gliomas and to correlate the IDH1 positivity with the type and grade of tumors, the age and sex of the patients.

MATERIAL AND METHODS: A retroâ€“ and prospective case series study. One hundred and nine cases of intracranial gliomas were collected between 2008 and 2014 from Mosul Private Laboratories and Al-Jamboree Teaching Hospitals in Mosul. IDH1 mutations were assessed immunohistochemically using anti-IDH1 R132H mouse monoclonal antibody.

RESULTS: IDH1 mutation was perceived in 34.86% of gliomas. In adult gliomas, the secondary glioblastoma and the low-grade astrocytoma had the greatest values of IDH1 positivity (88.88% and 62.5% respectively), followed by oligoastrocytoma/oligodendroglioma (50.0%), and anaplastic astrocytoma (47.36%). The primary glioblastomsa showed 17.64% IDH1 positivity. Males and females expressed the IDH1 equally. While, there was no role of IDH1 in pediatric gliomas.

CONCLUSION: IDH1 mutation is commonly present in adult gliomas particularly in low-grade gliomas, and secondary glioblastoma, with equal sex distribution, but it has no role in pediatric gliomas.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, et al, Astrocytic tumors. In: David N. Louis DN, Ohgaki H, Wiestler OD, Webster K. Cavenee WK. WHO Classification of Tumors of the Central Nervous System. France: IARC, Lyon; 2007, P:14-80.

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, and Von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumor. Act Neuropathol. 2008; 116:597-602. DOI: https://doi.org/10.1007/s00401-008-0455-2

Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but are rare in primary glioblastomas. Neuro Oncol. 2009; 11:341-347. DOI: https://doi.org/10.1215/15228517-2009-025

Watanabe T, Nobusawa S, Kleihues P, and Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009; 174:1149-1153. DOI: https://doi.org/10.2353/ajpath.2009.080958

Capper D, WeiBert S, Balss J, Habel A, Meyer J, Jaer D, et al. Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. Brain Pathol. 2010; 20;245-254. DOI: https://doi.org/10.1111/j.1750-3639.2009.00352.x

Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science. 2009; 100:1996-1998. DOI: https://doi.org/10.1111/j.1349-7006.2009.01270.x

Margittai E, and BÃ¡nhegyi G. Isocitrate dehydrogenase: a NADPH-generating enzyme in the lumen of the endoplasmic reticulum. Arch Biochem Biophys. 2008; 471:184â€“190. DOI: https://doi.org/10.1016/j.abb.2007.12.017

Capper D, WeiBert S, Balss J, Habel A, Meyer J, Jaer D, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009; 118:599-601. DOI: https://doi.org/10.1007/s00401-009-0595-z

Xu X, Zhao J, Xu Z, et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reval a noval self regulatory mechanism of activity. J Biol Chem. 2004; 279:946-957. DOI: https://doi.org/10.1074/jbc.M404298200

Ohgaki H, and Kleihues P, Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011; 28 (3):177-183. DOI: https://doi.org/10.1007/s10014-011-0029-1

Nobusawa S, and Yokoo H. IDH1/2 mutation in gliomas. Brain Nerve. 2011; 63(12):1378-1386.

Kaneko Mk, Tian W, Takano Sh, Suzuki H, Sawa Y, Hozumi Y, et al. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Bioch Biophys Res Comm. 2011;406:608-613 DOI: https://doi.org/10.1016/j.bbrc.2011.02.102

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducrary F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27:4150â€“4154. DOI: https://doi.org/10.1200/JCO.2009.21.9832

Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009; 118:469â€“474. DOI: https://doi.org/10.1007/s00401-009-0561-9

Nobusawa S, Watanabe T, Kleihus P, et al. IDH1 mutation as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009; 15:6002-6007. DOI: https://doi.org/10.1158/1078-0432.CCR-09-0715

Tabatabai Gh, Stupp R, Van Den Bent MJ, Hegi ME, Tobn JC, Wick W, et al. Molecular diagnostics of gliomas :the clinical perspective. Acta Neuropathol. 2010; 120:585-592. DOI: https://doi.org/10.1007/s00401-010-0750-6

Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010; 119:487â€“494. DOI: https://doi.org/10.1007/s00401-010-0645-6

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360:765â€“773. DOI: https://doi.org/10.1056/NEJMoa0808710

Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, et al. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol. 2012; 108(3):361-373. DOI: https://doi.org/10.1007/s11060-012-0837-0

Hartmann Ch, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010; 120(6);707-718. DOI: https://doi.org/10.1007/s00401-010-0781-z

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach J, Schramm J, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translation study of the German Glioma Network. J Clin Oncol. 2009; 27(34):5743-5750. DOI: https://doi.org/10.1200/JCO.2009.23.0805

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, P. Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807â€“1812. DOI: https://doi.org/10.1126/science.1164382

Leibetseder A, Michael Ackerl M, Flechl B, WÃ¶hrer A, Widhalm G, Dieckmann K. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro Oncol. 2013; 15(1):112-121. DOI: https://doi.org/10.1093/neuonc/nos283

Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, LaFramboise WA et al. IDH1 mutations are common in malignant gliomas arising in adolescent: a report from the Childrenâ€™s Oncology Group. Childs Nerv Syst. 2011; 27(1):87-94. DOI: https://doi.org/10.1007/s00381-010-1264-1

Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer. 2011; 128:1095â€“1103. DOI: https://doi.org/10.1002/ijc.25448

Jha P, Suri V, Sharma V, Singh G, SharmaMC, Pathak p et al. IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Exper Mol Pathol. 2011; 91:385â€“393. DOI: https://doi.org/10.1016/j.yexmp.2011.04.017

Labussiere M, Marc Sanson M, Idbaih A and Delattre JY. IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy? The Oncologist. 2010;15;196-199. DOI: https://doi.org/10.1634/theoncologist.2009-0218

Rivera-Zengotita M, and Yachnis AT. Gliosis versus glioma? Donâ€™t grade until you know. Adv Anat Pathol. 2012; 19(4):239-249. DOI: https://doi.org/10.1097/PAP.0b013e31825c6a04

Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, and Nutt CL. Mutant IDH1-specific immunohisochemistry distinguishes diffuse astrocytoma from astrocytosis. Act Neuropathol. 2010; 119:509-511. DOI: https://doi.org/10.1007/s00401-009-0632-y

Song X, Allen RA, Dunn ST, Fung KM, Farmer P, Gandhi S, et al. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol. 2011; 4(7):651-660.

Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010; 28:3061-3068. DOI: https://doi.org/10.1200/JCO.2009.26.7252

Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009; 118:401â€“405. DOI: https://doi.org/10.1007/s00401-009-0550-z

Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010 Sep;99(2):209-15. DOI: https://doi.org/10.1007/s11060-010-0129-5

Van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010; 16:1597â€“1604. DOI: https://doi.org/10.1158/1078-0432.CCR-09-2902

Tareq A. Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 2012; 108:403â€“410. DOI: https://doi.org/10.1007/s11060-012-0844-1